Skip to main content
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. — Investor Relations & Filings

Ticker · PTHS ISIN · US1711261057 US Manufacturing
Open in API
Filings indexed 205 across all filing types
Latest filing 2023-05-01 Capital/Financing Update
Country US United States of America
Listing US PTHS

About Pelthos Therapeutics Inc.

https://ir.pelthos.com/

Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing innovative therapeutic products for patients with unmet medical needs. Its lead product is ZELSUVMI™ (berdazimer topical gel, 10.3%), the first FDA-approved, at-home prescription treatment for molluscum contagiosum. ZELSUVMI is based on the company's proprietary nitric oxide-releasing technology platform, NITRICIL™, which is also being utilized for a pipeline of other product candidates. The company's portfolio also includes the acquired asset Xepi (ozenoxacin) Cream, 1%.

Recent filings

Filing Released Lang Actions
S-1/A
Capital/Financing Update Classification · 100% confidence The document is a Form S-1/A, which is an amendment to a registration statement filed with the SEC under the Securities Act of 1933. It is related to an initial public offering (IPO) of units consisting of common stock and warrants. The text includes detailed disclosures typical of a registration statement for securities offerings, including information about the offering, selling stockholders, use of proceeds, risk factors, and underwriting. This type of filing is a capital markets document related to fundraising and issuance of new securities. It is not an annual report, earnings release, or any other type of report. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is the actual registration statement, not just an announcement or a certification, so it is not RPA or RNS.
2023-05-01 English
Regulatory Filings 2023
Regulatory Filings
2023-01-23 English
S-1/A
Regulatory Filings Classification · 100% confidence The document is an Amendment No. 1 to a Form S-1 Registration Statement filed with the SEC, which is a registration statement for securities under the Securities Act of 1933. It includes detailed information about indemnification of directors and officers, recent sales of unregistered securities, exhibits, and undertakings related to the registration process. The document is not a financial report, earnings release, or management discussion but a regulatory filing related to securities registration. Form S-1 and its amendments are regulatory filings for initial public offerings or other securities offerings, not annual or quarterly reports or other categories listed. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement but a substantive regulatory filing.
2023-01-20 English
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a correspondence letter from Chromocell Therapeutics Corporation to the SEC staff responding to comments on an Amendment No. 1 to Draft Registration Statement on Form S-1. It addresses SEC staff comments on disclosures related to the Registration Statement, including use of proceeds, management's discussion and analysis, critical accounting estimates, business strategy, and intellectual property. The document is not the Registration Statement itself but a response letter discussing revisions made to the Registration Statement. It is a regulatory correspondence related to a registration filing, not a financial report, earnings release, or other specific report type. The document length is about 6300 characters, and it is a letter format responding to SEC comments, which fits the Regulatory Filings (RNS) category as a fallback for miscellaneous regulatory correspondence that does not fit other categories.
2023-01-11 English
S-1
Capital/Financing Update Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used for initial public offerings (IPOs) to register securities for sale to the public. It contains detailed information about the offering, including the securities being registered, the company details, underwriters, and risk factors. This is not an annual report, earnings release, or any other type of periodic financial report. It is a capital markets filing related to the company's initial public offering and registration of securities. According to the filing definitions, updates on company fundraising or capital structure changes, including IPO registration statements, fall under Capital/Financing Update (CAP). Therefore, the correct classification is CAP.
2023-01-11 English
Regulatory Filings 2022
Regulatory Filings
2022-10-31 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.